Omeros (NASDAQ:OMER) CAO Sells $369,300.00 in Stock

Omeros Corporation (NASDAQ:OMER) CAO David Borges sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total value of $369,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Omeros Price Performance

Shares of NASDAQ OMER opened at $12.01 on Friday. The stock has a market capitalization of $851.51 million, a P/E ratio of -5.95 and a beta of 2.38. Omeros Corporation has a one year low of $2.95 and a one year high of $17.65. The firm’s 50 day simple moving average is $11.16 and its two-hundred day simple moving average is $6.96.

Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.39. As a group, equities analysts expect that Omeros Corporation will post -3.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Omeros by 9.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 31,728 shares of the biopharmaceutical company’s stock valued at $545,000 after purchasing an additional 2,631 shares in the last quarter. Harbour Investments Inc. lifted its holdings in Omeros by 46.1% in the second quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 4,251 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of Omeros by 113.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 5,677 shares during the period. Rhumbline Advisers raised its position in shares of Omeros by 7.1% in the 3rd quarter. Rhumbline Advisers now owns 105,873 shares of the biopharmaceutical company’s stock worth $434,000 after acquiring an additional 7,048 shares in the last quarter. Finally, Cypress Capital Group lifted its stake in shares of Omeros by 20.7% in the 2nd quarter. Cypress Capital Group now owns 42,000 shares of the biopharmaceutical company’s stock valued at $126,000 after purchasing an additional 7,200 shares during the period. 48.79% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on OMER shares. Weiss Ratings restated a “sell (d-)” rating on shares of Omeros in a report on Wednesday, October 8th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Wednesday, October 15th. HC Wainwright lifted their target price on shares of Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Wall Street Zen cut shares of Omeros from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Finally, WBB Securities reissued a “strong-buy” rating and issued a $45.00 price target on shares of Omeros in a report on Wednesday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Omeros has a consensus rating of “Moderate Buy” and an average target price of $40.33.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.